Bank of New York Mellon
LVTX

Bank of New York Mellon’s LAVA Therapeutics LVTX Stock Holding History

Bank of New York Mellon’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,173
Closed -$45K – 4579
2022
Q2 		$45K Sell
15,173
-2,474
-14% -$8.58K ﹤0.01% 4364
2022
Q1 		$78K Hold
17,647
– – ﹤0.01% 4450
2021
Q4 		$97K Hold
17,647
– – ﹤0.01% 4403
2021
Q3 		$104K Sell
17,647
-7,641
-30% -$55K ﹤0.01% 4328
2021
Q2 		$275K Sell
25,288
-9,031
-26% -$112K ﹤0.01% 3989
2021
Q1 		$521K Buy
+34,319
New +$471K ﹤0.01% 3663

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon's LVTX Position: Q3 2022 in Review

Bank of New York Mellon sold out of LAVA Therapeutics (LVTX) in Q3 2022, closing a stake of 15,173 shares — an estimated $45K sold.

Bank of New York Mellon first reported a position in LVTX in Q1 2021 and held it in 6 quarters. The position peaked at $521K in Q1 2021. 13 funds tracked by Wall St. Rank hold LVTX as of Q3 2022.

  • Bank of New York Mellon reported no remaining LAVA Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 15,173 LAVA Therapeutics shares in Q3 2022, an estimated $45K.
  • Bank of New York Mellon first reported a position in LAVA Therapeutics in Q1 2021 and held it in 6 quarters.
  • Bank of New York Mellon's LAVA Therapeutics position peaked at $521K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2022.

Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.